Are all individuals equally sensitive in the blood pressure to high salt intake?

Acta Physiologica Hungarica

Volumn 95, Issue 3, 2008, Pages 247-265

  Katori, M ^a,b   Majima, M ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

Brown Norway Katholiek rats; Ebelactone B; Hypertension; Kidney; Kinins; Poststatin; Potassium intake; Renal kallikrein; Salt sensitivity; Urinary kininases

Indexed keywords

ANIMAL; HUMAN; KALLIKREIN KININ SYSTEM; KIDNEY; PATHOPHYSIOLOGY; PHYSIOLOGY; POTASSIUM INTAKE; RENOVASCULAR HYPERTENSION; REVIEW; SALT INTAKE;

ANIMALS; HUMANS; HYPERTENSION, RENAL; KALLIKREIN-KININ SYSTEM; KIDNEY; POTASSIUM, DIETARY; SODIUM CHLORIDE, DIETARY;

EID: 49249093066     PISSN: 0231424X     EISSN: 15882683     Source Type: Journal    
DOI: 10.1556/APhysiol.95.2008.3.2     Document Type: Review

References (94)

1. Elliott P, Dyer A, Stamler R: The INTERSALT study: results for 24 hour sodium and potassium, by age and sex. INTERSALT Co-operative Research Group. J. Hum. Hypertens. 3, 323-330 (1989)
2. Elliott P, Mamot M, Dyer A, Joossens J, Kesteloot H, Stamler R, Stamler J, Rose G: The INTERSALT study: main results, conclusions and some implications. Clin. Exp. Hypertens. A. 11, 1025-1034 (1989)
3. Jones D: Dietary sodium and blood pressure. Hypertension 44, e12 (2004)
4. Davis M, Jones D: The role of lifestyle management in the overall treatment plan for prevention and management of hypertension. Semin. Nephrol. 22, 35-43 (2002)
5. Jones D: What is the role of obesity in hypertension and target organ injury in African American? Am. J. Med. Sci., 317, 147-151 (1999)
6. Weinberger M: Salt sensitivity of blood pressure in humans. Hypertension 27, 4411-4490 (1996)
7. Weinberger M: Salt sensitivity; does it play an important role in the pathogenesis and treatment of hypertension? Curr. Opin. Nephrol. Hypertens. 5, 205-208 (1996)
8. Weinberger M: Salt and blood pressure. Curr. Opin. Nephrol. Hypertens. 15, 254-257 (2000)
9. Weinberger M: More on the sodium saga. Hypertension 44, 609-611 (2004)
10. Weinberger M: Sodium and blood pressure. Curr. Opin. Cardiol. 19, 353-356 (2004)
11. Katori M, Majima M: The renal kallikrein-kinin system: Its role as a safety valve for excess sodium intake, and its attenuation as a possible etiologic factor in salt-sensitive hypertension. Crit. Rev. Clin. Lab. Sci. 40, 43-115 (2003)
12. Obarzanek E, Proschan M, Vollmer W, Moore T, Sacks F, Appel L, Svetkey L, Most-Winchauser M, Cutler J: Individual blood pressure responses to changes in salt take: results from the DASH-Sodium trial. Hypertension 42, 459-467 (2003)
13. Kawasaki T, Delea C, Bartter F, Smith H: The effect of high-sodium and low-sodium intake on blood pressure and other related variables in human subjects with idopathic hypertension. Am. J. Med. 64, 193-198 (1978)
14. Weinberger M, Miller J, Luft F, Grim C, Fineberg N: Definitions and characteristics of sodium sensitivity and resistance of blood pressure. Hypertension 8(6 Pt 2), Suppl II, 127-134 (1986)
15. Weinberger M, Fineberg N: Sodium and volume sensitivity of blood pressure. Age and pressure change over time. Hypertension. 18, 67-71 (1991)
16. Katori M, Majima M: A missing link between a high salt intake and blood pressure increase. J. Pharmacol. Sci., 100, 370-390 (2006)
17. Crowley S, Gurley S, Oliverio M, Pazmino A, Griffiths R, Flannery P, Spurney RF, Kim H-S, Oliver S, Le TH, Coffman TM: Distinct role for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J. Clin. Invest. 115, 1092-1099 (2005)
18. Majima M, Katori M: Approaches to the development of novel antihypertensive drugs: Crucial role of the renal kallikrein-kinin system. Trends Pharmacol. Sci. 16, 239-246 (1995)
19. Katori M, Majima M: Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship. Jpn. J. Pharmacol. 70, 95-128 (1996)
20. Katori M, Majima M: Preventive role of renal kallikrein-kinin system in the early phase of hypertension and development of new antihypertensive drugs. Adv. Pharmacol. 44, 147-224 (1998)
21. Maddox D, Brenner B (1996): Glomerular Ultrafiltration. In: The Kidney. Vol. 1, Eds Brenner B, W.B. Saunders Company, Philadelphia, London, Toronto, Montreal, Sydney, Tokyo, pp. 286-333
22. Orstabik T, Nustad K, Brandtzadeeg P, Pierce J: Cellular origin of urinary kallikrein. J. Histochem. Cytochem. 24, 1037-1039 (1976)
23. Orstavvik T, Inagami T: Localization of kallikrein in the rat kidney and its anatomical relationship to renin. J. Histochem. Cytochem., 30, 385-390 (1982)
24. Vio CP, Figueroa CD: Subcellular localization of renal kallikrein by ultrastructural immunochemistry. Kidney Int. 28, 36-42 (1985)
25. Figueroa CD, Caorsi I, Vio CP: Visualization of renal kallikrein in luminal and basolateral membranes. J. Histochem. Cytochem. 32, 1238-1240 (1984)
26. Figueroa C, MacIver A, Mackenzie J, Bhoola K: Localization of immunoreactive kininogen and tissue kallikrein in the human nephron. Histochemistry 89, 437-442 (1988)
27. Fujita T, Kumagai Y, Ikeda Y, Inamura N, Iwata T, Ogino M, Majima M: Involvement of the renal kallikrein-kinin system in furosemide-induced natriuresis in rats. Jpn. J. Pharmacol. 84, 133-139 (2000)
28. Seino M, Abe M, Irokawa N, Ito T, Yasujima M, Sakurai Y, Chiba S, Saito K, Ritz K, Kusaka T, Miyazaki S, Yoshinaga K: Effect of furosemide on urinary kallikrein excretion in patients with essential hypertension. Tohoku J. Exp. Med. 124, 197-203 (1978)
29. Zschiedrich H, Fleckenstein P, Geiger R, Fink E, Sinterhauf K, Philipp T, Philipp T, Distler A: Urinary kallikrein in normotensive subjects and in patients with essential hypertension. Clin. Exp. Hypertens. 2, 693-708 (1980)
30. Majima M, Katori M, Ogino M, Saito M, Sugimoto K, Adachi K, Sunahara N, Katoh K, Tatemachi N, Takei Y: Failure of endogenous blood kinin levels elevated by captopril to induce hypotension in normotensive and hypertensive rats. An assay for kinin by a new ELISA. Biochem. Res. 17, 698-708 (1993)
31. Majima M, Katori M, Ogino M, Saito M, Sugimoto K, Adachi K, Ohno T, Sunahara N, Katoh K, Tatemachi N, Takei Y: Lack of contribution of circulatory kinin elevated by captopril to induce hypotension in normotensive and hypertensive rats. Immunopharmacology 33, 291-293 (1996)
32. Saito M, Majima M, Katori M, Sanjou Y, Suyama I, Shiokawa H, Koshiba K, Aoyagi T: Degradation of bradykinin in human urine by carboxypeptidase Y-like exopeptidase and neutral endopeptidase and their inhibition by ebelactone B and phosphoramidon. Int. J. Tissue React. 17, 181-190 (1995)
33. Majima M, Kuribayashi Y, Ikeda Y, Adachi K, Kato H, Katori M, Aoyagi T: Diuretic and natriuretic effect of ebelactone B in anesthetized rats by inhibition of a urinary carboxypeptidase Y-like kininase. Jpn. J. Pharmacol. 65, 79-82 (1995)
34. Majima M, Shima C, Saito M, Kuribayashi Y, Katori M, Aoyagi T: Poststatin, a novel inhibitor of bradykinin-degrading enzymes in rat urine. Eur. J. Pharmacol. 232, 181-190 (1993)
35. Chao J, Chen LM, Xiong W, Chao S, Woodley-miller C, Wang L, Lu HS, Chao L: Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J. Biol. Chem. 265, 16394-16401 (1990)
36. Yang T, Terada Y, Nonoguchi H, Tsujino M, Tomita K, Marumo F: Distribution of kallikrein-binding protein mRNA in kidneys and difference between SHR and WKY. Am. J. Physiol. 267, F325-330 (1994)
37. 163 to threonine is responsible for the defective secretion of high molecular weight kininogen by the liver of Brown Norway Katholiek rats. J. Biol. Chem. 268, 17219-17224 (1993)
38. Majima M, Yoshida O, Mihara H, Muto T, Mizogami S, Kuribayashi Y, Katori M, Oh-ishi S: High sensitivity to salt in kininogen-deficient Brown Norway Katholiek rats. Hypertension 22, 705-714 (1993)
39. Rhaleb N-E, Yang XP, Nanba M, Shesely EG, Carretero OA: Effect of chronic blockade of the kallikrein-kinin system on the development of hypertension in rats. Hypertension 37, 121-128 (2001)
40. Madeddu P, Varoni M, Palomba D, Emanueli C, Demontis MP, Gilorioso N, Gilorioso N, Dessl-Flgheri P, Sarizarni R, Anaia V: Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation 96, 3570-3578 (1997)
41. Alfie ME, Yang XP, Hess F, Carretero OA: Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem. Biophys. Res. Commun. 224, 625-630 (1996)
42. 2 receptors. Hypertension 29, 483-487 (1997)
43. Majima M, Mizogami S, Kuribayashi Y, Katori M, Oh-ishi S: Hypertension induced by a nonpressor dose of angiotensin II in kininogen-deficient rats. Hypertension 24, 111-119 (1994)
44. Ward PE, Margolius HS (1979): Renal and urinary kallikrein. In: Bradykinin, Kallidin and Kallikrein. Vol. 25 (Suppl.), Ed. Erd's E, Springer-Verlag, Berlin, Heidelberg, New York, pp. 525-548
45. Levinskey NG: The renal kallikrein-kinin system. Circ. Res. 44, 441-451 (1979)
46. Carretero OA, Scicli AG: The renal kallikrein-kinin system. Am. J. Physiol. 238, F247-255 (1980)
47. Mayfield RK, Margolius HS: Renal kallikrein-kinin system. Relation to renal function and blood pressure. Am. J. Nephrol. 3, 145-155 (1983)
48. Scicli AG, Carretero OA: Renal kallikrein-kinin system. Kidney Int. 29, 120-130 (1986)
49. Margolius HS: Tissue kallikreins and kinins: Regulation and roles in hypertensive and diabetic diseases. Annu. Rev. Pharmacol. 29, 343-364 (1989)
50. Carretero OA, Scicli AG (1990): Kinins as regulators of blood flow and blood pressure. In: Hypertension: Pathology, Diagnosis, and Management. Eds. Laragh J, Brenner B., Raven Press, New York, pp. 805-817
51. Margolius HS: Kallikreins and kinins. Some unanswered questions about system characteristics and roles in human disease. Hypertension 26, 221-229 (1995)
52. Mohsin SSJ, Majima M, Katori M, Sharma JN: Important suppressive roles of the kallikrein-kinin system during the developmental stage of hypertension in spontaneously hypertensive rats. Asia Pacific J. Pharmacol. 7, 73-82 (1992)
53. Carretero OA, Polomski C, Hampton A, Scicli AG: Urinary kallikrein, plasma renin and aldosterone in New Zealand genetically hypertensive (GH) rats. Clin. Exp. Pharmacol. Physiol. 3(Suppl.), 55-59 (1976)
54. Gilboa N, Rudofsky U, Margo A: Urinary and renal kallikrein in hypertensive fawn-hooded (FH/Wjd) rats. Lab. Invest. 50, 72-78 (1984)
55. Porcelli G, Bianchi G, Croxatto HR: Urinary kallikrein excretion in a spontaneously hypertensive strain of rats. Proc. Natl. Acad. Sci. USA. 149, 983-986 (1975)
56. Arbeit LA, Serra SR: Decreased total and active urinary kallikrein in normotensive Dahl salt susceptible rats. Kidney Int. 28, 440-446 (1985)
57. Rapp JP, Tan SY, Margolius HS: Plasma mineral corticoids, plasma renin, and urinary kallikrein in saltsensitive and salt-resistant rats. Endocr. Res. Commun. 5, 35-41 (1978)
58. Majima M, Katori M, Hanazuka M, Mizogami S, Nakano T, Nakao Y, Mikami R, Uryu H, Okamura R, Mohsin SSJ, Oh-ishi S: Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system. Hypertension 17, 806-813 (1991)
59. Ito H, Majima M, Nakajima S, Hayashi I, Katori M, Izumi T: Effect of prolonged administration of a urinary kininase inhibitor, ebelactone B on the development of doxycorticosterone acetate-salt hypertension in rats. Br. J. Pharmacol. 126, 613-620 (1999)
60. Hayashi I, Majima M, Fujita T, Okumura T, Kumagai Y, Tomita N, Morishita R, Higaki J, Ogiwara T: In vivo transfer of antisense oligonucleotide against urinary kininase blunts deoxycorticosterone acetate-salt hypertension in rats. Br. J. Pharmacol. 131, 820-826 (2000)
61. Majima M, Adachi K, Kuribayashi Y, Mizogami S, Katori M: Increase in vascular sensitivity to angiotensin II and epinephrine after four-day infusion of 0.3 M sodium chloride in conscious kininogendeficient Brown Norway Katholiek rats. Jpn. J. Pharmacol. 69, 149-158 (1995)
62. Sasaki S, Takeda K, Okajima H, Takahashi H, Yoshimura M, Nakagawa M, Itiji H: Pressor responses to intracisternal injection of hypertonic NaCl in rats. J. Cardiovasc. Pharmacol. 6, 349-364 (2000)
63. Campese V, Karubian F, Chervu I, Parise M, Sarkies N, Bigazzi R.: Pressor reactivity to norepinephrine and angiotensin in salt-sensitive hypertensive patients. Hypertension 21, 301-307 (1993)
64. Elliot AH, Nuzum FR: The urinary excretion of a depressor substance (kallikrein of Frey and Kraut) in arterial hypertension. Endocrinology 18, 462-474 (1934)
65. Margolius HS, Geller RG, Pisano JJ, Sjoerdsma A: Altered urinary kallikrein excretion in human hypertension. Lancet ii, 1063-1065 (1971)
66. Carretero OA, Scicli AG: The kallikrein-kinin system in human and in experimental hypertension. Klin. Wochenschr. 56(Suppl. 1), 113-125 (1978)
67. Levy SB, Lilly JJ, Frigon RP, Stone LA: Urinary kallikrein and plasma renin activity as determinants of renal blood flow. J. Clin. Invest. 60, 129-138 (1977)
68. Zinner SH, Margolius HS, Rosner B, Keiser HR, Rass EH: Familial aggregation of urinary kallikrein concentration in childhood: relation to blood pressure, race and urinary electrolytes. Am. J. Epidemiol. 104, 124-132 (1976)
69. Zinner SH, Margolius HS, Rosner B, Kass EH: Stability of blood pressure rank and urinary kallikrein concentration in childhood: An eight-year follow-up. Circulation 58, 908-915 (1978)
70. Hunt SC, Hasstedt SJ, Wu LL, Williams RR: A gene-enviromental interaction between inferred kallikrein genotype and potassium. Hypertension 22, 161-168 (1993)
71. Barlow R, Connell M, Levendig B, Gear J, Milne F: A comparative study of urinary sodium and potassium excretion in normotensive urban black and white South African males. S. Af. Med. J. 62, 939-941 (1982)
72. Barlow R, Connell M, Milne F: A study of 48-hour faecal and urinary electrolyte excretion in normotensive black and white South African males. J. Hypertens. 4, 197-200 (1986)
73. Luft F, Grim C, Fineberg N, Weinberger M: Effects of volume expansion and contraction in normotensive whites, blacks and subjects of different ages. Circulation 59, 643-650 (1979)
74. Pratt JH, Rebhun JF, Zhou L, Ambrosius WT, Newman SA, Gomex-Sanchez CE, Mayers DF: Levels of mineralocorticoids in whites and blacks. Hypertension 34, 315-319 (1999)
75. Luft F, Rankin L, Bloch R, Weyman A, Willis L, Murray R, Grim C, Weinberger M: Cardiovascular and humoral responses to extreme of sodium intake in normal black and white men. Circulation 60, 697-706 (1979)
76. Whelton P, He J, Cutler J, Brancati F, Appel L, Follmann D, Klag M: Effects of oral potassium on blood pressure, meta-analysis of randomized controlled trials. J. Am. Med. Assoc. 277, 1624-1632 (1997)
77. Morris RCJ, Sebastian A, Forman A, Tanaka K, Schmidlin O: Normotensive salt sensitivity. Effects of race and dietary potassium. Hypertension 33, 18-23 (1999)
78. Bailin L, Rouse I, Armstrong B, Margetts B, Vandongen R: Vegetarian diet and blood pressure levels: incidental or causal association? Am. J. Clin. Nutr. 48, 806-810 (1988)
79. Schmidlin O, Forman A, Tanaka M, Sebastian A, Morris RCJ: NaCl-induced renal vasoconstriction in salt-sensitive African Americans. Antipressor and hemodynamic effects of potassium bicarbonate. Hypertension 33, 633-639 (1999)
80. Williams RR, Hunt SC, Hoplins P, Wu L, Hasstedt SJ, Berry TD, Barlow GK, Lifton RP, Lalouel JM: Genetic basis of familial dyslipidemia and hypertension: 15-years results from Utah. Am. J. Hypertens. 6, 319S-327S (1993)
81. Staessen JA, Birkheger W, Bulpitt CJ, Fagard R, Fletcher AF, Lijnen P, Thijis I, Amery A: The relationship between blood pressure and sodium and potassium excretion during the day and night. J. Hypertens. 11, 443-447 (1993)
82. Ueno M, Kawasaki T, Uezono K, Omae T, Matsuoka M: Relationship of urinary kallikrein excretion to renal water and sodium excretion. Metabolism 32, 433-437 (1983)
83. Albano J, Campbell S, Farrer A, Millar J: Gender differences in urinary kallikrein excretion in man: variation throughout the menstrual cycle. Clin. Sci. (London) 86, 227-231 (1994)
84. Kailasam M, Martinez J, Cervenka J, Yen S, O'connor D, Parmer R: Racial differences in renal kallikrein excretion: effect of the ovulatory cycle. Kidney Int. 54, 1652-1658 (1998)
85. Horwitz D, Margolius HS, Keiser HR: Effects of dietary potassium and race on urinary excretion of kallikrein and aldosterone in man. J. Clin. Endocrinol. Metab. 47, 296-299 (1978)
86. Smith GJ, Klotman PE, Sventkey LP: Potassium chloride lowers blood pressure and caused natriuresis in older patients with hypertension. J. Am. Soc. Nephrol. 2, 1302-1309 (1992)
87. Muto S: Potassium transport in the mammalian collecting duct. Physiol. Rev. 81, 85-116 (2001)
88. Vio CP, Figueroa CD: Evidence for a stimulatory effect of high potassium diet on renal kallikrein. Kidney Int. 31, 1327-1334 (1987)
89. +-induced diuresis and natriuresis in anesthetized rats. Eur. J. Pharmacol. 399, 223-227 (2000)
90. Hayashi I: A secretary mechanism of renal kallikrein by a high potassium ion; a possible involvement of ATP-sensitive potassium channel. Immunopharmacology 44, 49-55 (1999)
91. Fujita T, Hayashi I, Kumagai Y, Imamura N, Majima M: Early increase in renal kallikrein excretion on administration of potassium or ATP-sensitive potassium channel blockers in rats. Br. J. Pharmacol. 128, 1275-1283 (1999)
92. + channel blocker: comparison with rat insulinoma cells. Mol. Pharmacol. 46, 139-145 (1994)
93. Bönner G, Thieven B, Rütten H, Chrosch R, Krone W: Renal kallikrein is a determinant of salt sensitivity. J. Hypertens. 11(Suppl. 5), S210-211 (1993)
94. Ferri C, Bellini C, Carlomagno A, Perrone A, Santucci A: Urinary kallikrein and salt sensitivity in essential hypertensive males. Kidney Int. 46, 780-788 (1994).